AbbVie, Inc. (ABBV)

AbbVie's stock has risen by 15.3% in the past six months, reaching a 52-week high of $244.81 in October 2025. The company reported strong financial results for Q3 and Q4 2025, exceeding earnings and revenue expectations, with full-year 2025 revenue reaching $61.16 billion. Despite positive earnings, the stock experienced a sell-off in early February 2026 due to softer-than-expected Q1 2026 guidance. AbbVie has also expanded its operations through acquisitions of Capstan Therapeutics and Gilgamesh Pharmaceuticals, and signed a licensing agreement with RemeGen.

AbbVie's business generally does not experience significant seasonality. However, product revenues can be influenced by end-customer and retail buying patterns, as well as wholesaler inventory levels.

AbbVie Inc. is a global biopharmaceutical company focused on researching, developing, manufacturing, and selling advanced therapies for complex health conditions. AbbVie operates in the Pharmaceuticals & Biotech sector, specifically the Biotechnology industry, with key therapeutic areas including immunology, oncology, neuroscience, ophthalmology, and aesthetics. The company's major products include Humira, Skyrizi, and Rinvoq for immunology; Imbruvica, Venclexta, and Epkinly for oncology; Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta for neuroscience; Botox Cosmetic, CoolSculpting, and Juvederm fillers for aesthetics; and Mavyret for Hepatitis C.

AbbVie operates globally, serving patients in over 170 countries, with its headquarters in North Chicago, Illinois. The company has a significant manufacturing and research presence in the United States, along with R&D sites in California, Massachusetts, Germany, and Japan.

AbbVie's brand reputation has been influenced by its strong product portfolio and financial performance, as well as controversies related to its business practices. The company has faced accusations of using anti-competitive patent strategies to delay biosimilar market entry, particularly for Humira. AbbVie has settled lawsuits related to alleged kickback schemes and faced criticism for its patent system practices and pricing. In September 2025, AbbVie settled litigation regarding Rinvoq, preventing generic versions from entering the U.S. market before April 2037.

AbbVie Inc. has a diverse ownership structure, with institutional investors holding approximately 42.46% of the stock. Major institutional owners include Vanguard Group Inc, BlackRock, Inc., State Street Corp, JPMorgan Chase & Co, Morgan Stanley, and Capital Research Global Investors. Insiders own about 0.07% of the stock, while public companies and individual investors collectively hold approximately 57.47%.